Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T15:52:06.605Z.
Calculation as of: 2026-10-06T15:52:06.605Z.
Quote observation: 2026-10-06T15:50:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 53f0b653117dfddf80d57e74ba570551200adc0db5709ea8e1a3c029d43ac92d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
MBX Biosciences, Inc. Common Stock
Market Cap
$2.73B
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.70B
EV/Sales Ratio
1.51x
TTM Avg
1.36x
3Y Avg
1.94x
5Y Avg
2.46x
Market Cap
$2.69B
EV/Sales Ratio
1.57x
TTM Avg
1.35x
3Y Avg
1.18x
5Y Avg
1.10x
Market Cap
$2.82B
EV/Sales Ratio
4.81x
TTM Avg
7.37x
3Y Avg
10.06x
5Y Avg
14.84x
Market Cap
$2.63B
EV/Sales Ratio
17.04x
TTM Avg
29.76x
3Y Avg
20.24x
5Y Avg
5044.79x
Market Cap
$2.63B
EV/Sales Ratio
310.30x
TTM Avg
165.08x
3Y Avg
106.18x
5Y Avg
84.28x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MBX Biosciences, Inc. Common Stock (MBX) | $2.73B | N/A | N/A | N/A | N/A |
| Precigen, Inc. (PGEN)vs › | $2.73B | 32.86x | 138.85x | 102.42x | 70.59x |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.70B | 1.51x | 1.36x | 1.94x | 2.46x |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 1.57x | 1.35x | 1.18x | 1.10x |
| Neogen Corporation (NEOG)vs › | $2.70B | 3.80x | 3.02x | 3.50x | 4.62x |
| AtriCure, Inc. (ATRC)vs › | $2.79B | 4.73x | 3.13x | 3.31x | 5.18x |
| TransMedics Group, Inc. (TMDX)vs › | $2.82B | 4.81x | 7.37x | 10.06x | 14.84x |
| Beam Therapeutics Inc. (BEAM)vs › | $2.63B | 17.04x | 29.76x | 20.24x | 5044.79x |
| NewAmsterdam Pharma Company N.V. (NAMS)vs › | $2.63B | 310.30x | 165.08x | 106.18x | 84.28x |
| Privia Health Group, Inc. (PRVA)vs › | $2.60B | N/A | 1.27x | 1.34x | 1.82x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
